# Doxazosin

## Doxaben XL 4mg

| 藥物代碼 | ODOX4 |
| :--- | :--- |
| 適應症 | Hypertension. Benign prostatic hyperplasia.\(B023711100\) |
| 副作用 | Dizziness, headache, fatigue, vertigo, edema & asthenia.Cardiovascular: Edema \(2.7% to 4%\), Hypotension \(1.7%-10%\)Gastrointestinal: Nausea \(1.2% to 4.3%\)Neurologic: Dizziness \(5.3% to 19%\), Headache \(4% to 15.8%\), Somnolence \(1.2% to 5%\), Vertigo \(1.5% to 7%\)Other: Fatigue \(8% to 12%\) |
| 禁忌 | Patients with known hypersensitivity to quinazolines, doxazosin or any of the          excipients of Doxaben/Doxaben XL. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Hypertension: 1-16mg qd or qhs. initially 1mg qhs, increase every1 or 2 wk of therapy to 2mg & thereafter at similar intervals to 4,8 & 16mg as determined by patient's response to achieve the desired BP reduction. Benign prostatic hyperplasia: Initially 1 mg once daily, may be increased to 2 mg & thereafter to 4 mg & 8 mg once daily. Recommened titration interval is 1-2WK. |
| 肝功能異常 | 無需調整劑量  嚴重肝功能障礙\(Child-Pugh C\)之病患不建議使用 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest moderate risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

